Security key
18978H508
CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
CUSIP: 18978H508
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 13
- Total 13F value
- $11
- Share change
- +13
- SEC-reported price per share
- $0.85
- Number of holders
- 1
- Value change
- +$11
- Number of buys
- 1
- Shares outstanding
- 1,614,040
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
1
Top holders
1
CNSP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
CNS Pharmaceuticals, Inc. SEC filings
CNS Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 18978H508
Recent filing periods:
Ownership snapshot
Top reported holders of CNSP - CNS Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Waldemar Priebe
Disclosed value leader
Waldemar Priebe
Comparable rows
0/11
Latest evidence
31 Mar 2025
3/4/5
13F
Highest disclosed value: $198,486
11 rows are not safely comparable across share classes.
Showing 1-6 of 11 holder rows.
Quick read
Waldemar Priebe has the largest disclosed position value at $198.5K.
0 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Waldemar Priebe's linked filing trail.
Disclosed position value
Top 5
Waldemar Priebe
$198.5K
Cortice Biosciences, Inc.
$172K
Carl Anthony Evans
$54.2K
UBS Group AG
$32.6K
Ground Swell Capital, LLC
$15.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Waldemar Priebe |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$198,486
156,807 shares
|
— | 06 Dec 2022 |
| Cortice Biosciences, Inc. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$172,010
573,368 shares
|
— | 30 Jul 2024 |
| Carl Anthony Evans |
3/4/5
Director
|
—
mixed-class rows
|
$54,165
501,001 shares
mixed-class rows
|
— | 08 Apr 2024 |
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$32,610
23,978 shares
|
— | 31 Mar 2025 |
| Ground Swell Capital, LLC |
13F
Company
|
—
class O/S missing
|
$15,424
11,341 shares
|
— | 31 Mar 2025 |
| Tower Research Capital LLC (TRC) |
13F
Company
|
—
class O/S missing
|
$6,951
5,111 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
13
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q4 2025 Across Filers
Q4 2025 holders
9
Q2 2025 holders
1
Holder diff
-8
| Investor | Q4 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend